Concepedia

Stephanie Ling

SL

11

Publications

1.1K

Citations

11

H-Index

2016

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

University of Cambridge

University of Glasgow

Cambridge University Hospitals NHS Foundation Trust

Cancer Research UK Scotland Institute

Stephanie Ling is an author at AstraZeneca (United Kingdom) specializing in biomedical imaging, molecular imaging, and engineering.

ORCID

Top concepts

Publications per year

2016–2024

11

Publications

11

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 327 citations · Full text

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 292 citations · Full text

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2019 · 155 citations · Full text

Universal Sample Preparation Unlocking Multimodal Molecular Tissue Imaging

Andreas Dannhorn, Emine Kazanç, Stephanie Ling et al. · Analytical Chemistry · 2020 · 112 citations

, , +17

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Christopher J. Tape, Stephanie Ling, Maria Dimitriadi et al. · Cell · 2016 · 79 citations · Full text

Rows per page

1–5 of 11